adMare BioInnovations and Medicine by Design Partner to Support Translation Priorities in the Toronto Life Sciences Ecosystem
Toronto, ON (October 17, 2022) – adMare BioInnovations (adMare) and Medicine by Design are pleased to announce their new memorandum of understanding (MOU) to support translation priorities, which will accelerate health innovation commercialization in the Toronto life sciences ecosystem and in Canada.
Medicine by Design is a convergence engine that undertakes transformative, multidisciplinary research in regenerative medicine and advances early-stage translation through strategic collaborations with leading commercialization accelerators. Under this MOU, adMare will contribute to advancing the translation of the most promising research projects that Medicine by Design is currently funding by extending their scientific and commercial expertise to Medicine by Design’s community of researchers. To this end, this partnership agreement includes a framework for adMare to have regular touchpoints with Medicine by Design’s pipeline of pre-clinical innovations.
“As adMare becomes further engaged with the Toronto life sciences ecosystem, we are thrilled to have the opportunity to be partnering with an organization such as Medicine by Design,” said Amie Phinney, senior director of partnerships at adMare. “Toronto is one of the country’s top hubs of life sciences innovations, and we look forward to working with Medicine by Design and all the ecosystem to transform the lives of millions of Canadians through the translation of the first-class research found here.”
The two organizations come together with a mutual interest in supporting, translating and commercializing research and innovation-related products emerging from discoveries made across the Toronto Academic Health Sciences Network (TAHSN), which includes University of Toronto and its affiliated hospitals.
Allison Brown, executive director of Medicine by Design added, “This memorandum of understanding marks the start to an exciting collaboration between us and adMare. We share the goal of improving human health through innovation, and this partnership ensures we will have multiple touchpoints to work toward that common goal while promoting excellence through regenerative medicine collaborations.”